UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinician Perspective on Once-Daily Zanubrutinib Dosing for B-Cell Malignancies at a Single Center

Clinical Medicine Insights. Oncology, 2024-01, Vol.18, p.11795549241275665

2024

Volltextzugriff (PDF)

Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes

Clinical lymphoma, myeloma and leukemia, 2017-09, Vol.17 (9), p.575-583.e2

2017

Volltextzugriff (PDF)

Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect® MM Registry

Blood cancer journal (New York), 2021-07, Vol.11 (7), p.134-134, Article 134

2021

Volltextzugriff (PDF)

CYSTS IN THE LUNG: A PECULIAR PRESENTATION

Chest, 2022-10, Vol.162 (4), p.A1252-A1252

2022

Volltextzugriff (PDF)

P915: TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI‐CD38 MONOCLONAL ANTIBODY: FINDINGS FROM THE CONNECT MM DISEASE REGISTRY

HemaSphere, 2023-08, Vol.7 (S3), p.e52503e2-n/a

2023

Volltextzugriff (PDF)

Connect MM Registry as a national reference for United States multiple myeloma patients

Cancer medicine (Malden, MA), 2020-01, Vol.9 (1), p.35-42

2020

Volltextzugriff (PDF)

Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States

EJHaem, 2023-02, Vol.4 (1), p.301-304

2023

Volltextzugriff (PDF)

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM

Blood advances, 2018-07, Vol.2 (13), p.1608-1615

2018

Volltextzugriff (PDF)

Optimization studies on the development of a blended fruit nectar based upon papaya (Carica papaya) and bottle gourd (Lagenaria siceraria)

British food journal (1966), 2013-06, Vol.115 (7), p.936-952

2013

Volltextzugriff (PDF)

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study

British journal of haematology, 2019-05, Vol.185 (3), p.492-502

2019

Volltextzugriff (PDF)

Refractory autoimmune thrombocytopenic purpura: Responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab)

American journal of hematology, 2003-12, Vol.74 (4), p.263-267

2003

Volltextzugriff (PDF)

A phase 2 expanded access study of zanubrutinib (ZANU) in patients (pts) with Waldenström Macroglobulinemia (WM)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e19522-e19522

2022

Volltextzugriff (PDF)

Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis

Cancer, 2020-10, Vol.126 (19), p.4332-4340

2020

Volltextzugriff (PDF)

A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis

Supportive care in cancer, 2022-07, Vol.30 (7), p.6135-6144

2022

Volltextzugriff (PDF)

Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.8035-8035

2021

Volltextzugriff (PDF)

Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry

Blood, 2022-11, Vol.140 (Supplement 1), p.13256-13258

2022

Volltextzugriff (PDF)

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry

Blood, 2022-11, Vol.140 (Supplement 1), p.8089-8091

2022

Volltextzugriff (PDF)

P-033 External Control Analysis for KarMMa-3: Idecabtagene Vicleucel (ide-cel) vs Real-World Standard of Care (RW SoC; Connect MM) for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S59-S60

2024

Volltextzugriff (PDF)

P-175 Real-World Minimal Residual Disease Testing Patterns: Findings From the Connect® MM Registry

Clinical lymphoma, myeloma and leukemia, 2024-09, Vol.24, p.S139-S140

2024

Volltextzugriff (PDF)

A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices

Supportive care in cancer, 2022-10, Vol.30 (10), p.7913-7922

2022

Volltextzugriff (PDF)

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study

Leukemia & lymphoma, 2022-10, Vol.63 (10), p.2383-2392

2022

Volltextzugriff (PDF)

Characteristics of long-surviving patients with multiple myeloma: Over 12 years of follow-up in the Connect MM Registry

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.8027-8027

2022

Volltextzugriff (PDF)

Recognition of early mortality in multiple myeloma by a prediction matrix

American journal of hematology, 2017-09, Vol.92 (9), p.915-923

2017

Volltextzugriff (PDF)

Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry

Annals of hematology, 2018-12, Vol.97 (12), p.2425-2436

2018

Volltextzugriff (PDF)

Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect ® Multiple Myeloma (MM) Disease Registry

Blood, 2021-11, Vol.138 (Supplement 1), p.117-117

2021

Volltextzugriff (PDF)

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(98)
Mit Volltextzugriff
(97)

Publikationsform

Sprache

Englisch
(109)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Clinician Perspective on Once-Daily Zanubrutinib Dosing for B-Cell Malignancies at a Single Center

Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes

Treatment patterns and outcomes in elderly patients with newly diagnosed multiple myeloma: results from the Connect® MM Registry

CYSTS IN THE LUNG: A PECULIAR PRESENTATION

P915: TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI‐CD38 MONOCLONAL ANTIBODY: FINDINGS FROM THE CONNECT MM DISEASE REGISTRY

Connect MM Registry as a national reference for United States multiple myeloma patients

Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM

Optimization studies on the development of a blended fruit nectar based upon papaya (Carica papaya) and bottle gourd (Lagenaria siceraria)

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study

Refractory autoimmune thrombocytopenic purpura: Responses to treatment with a recombinant antibody to lymphocyte membrane antigen CD20 (rituximab)

A phase 2 expanded access study of zanubrutinib (ZANU) in patients (pts) with Waldenström Macroglobulinemia (WM)

Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis

A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis

Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA

Outcomes of Second-Line (2L) Triplet+ Regimens in Patients with Relapsed/Refractory Multiple Myeloma (MM) Following Progression after First-Line (1L) Lenalidomide in the Connect® MM Disease Registry

Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect® MM Registry

P-033 External Control Analysis for KarMMa-3: Idecabtagene Vicleucel (ide-cel) vs Real-World Standard of Care (RW SoC; Connect MM) for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)

P-175 Real-World Minimal Residual Disease Testing Patterns: Findings From the Connect® MM Registry

A prospective study to evaluate febrile neutropenia incidence in patients receiving pegfilgrastim on-body injector vs other choices

Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study

Characteristics of long-surviving patients with multiple myeloma: Over 12 years of follow-up in the Connect MM Registry

Recognition of early mortality in multiple myeloma by a prediction matrix

Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect® MM Registry

Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect ® Multiple Myeloma (MM) Disease Registry

Suchergebnisse filtern